Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 301516

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 301516

License Grant
Licensor hereby grants to Licensee a royalty-bearing, sublicensable (with the right to sublicense through multiple tiers), exclusive license under Patents and Product Data to make, have made, use, import, offer to sell and sell Products in the Territory for use within the Field, subject to the right retained by Licensor to use the Product Data for its internal use for audits by the FDA or for other regulatory purposes not inconsistent with the terms of this Agreement.  

Trademark Assignment. As soon as practical, Licensor will transfer the rights to the Product Trademark to Licensee.

License Property
Patents means Licensor Pharma’s rights to the patents and patent applications listed to this Agreement; all non-provisional patent applications that claim priority to any of the provisional applications listed, provided that the claims of such non-provisional applications are entitled to claim priority to such provisional applications; all divisionals, continuations, and continuations-in-part of the non-provisional patent applications identified above, provided that the claims of such continuation-in-part are entitled to claim priority to at least one of the patent applications identified above; all reexaminations, reissues, extensions, renewals and foreign counterparts of any of the patents or patent applications identified above.

10,172,965 – High purity therapeutic bone agents
10,596,27 – High purity therapeutic bone agents

Product Data means Licensor Pharma’s rights to laboratory study data and reports; preclinical study data and reports; toxicology data and reports; grants and grant proposals; clinical laboratory assessments; manufacturing study data and reports; manufacturing processes, procedures and records; contract rights, reports, inspections and information; and other technical data and other work products and rights thereto that are directly related to the Product. For purposes of clarity, Product Data includes without limitation any and all samples of Product whether expired or otherwise, and records of such samples including but not limited to toxicology, formulation, preclinical, clinical records, batch records, laboratory reports and regulatory data or filings, FDA meeting minutes and regulatory correspondence.

“Product Trademarks” means Licensors rights to the registered trademark “CycloSam”.

Field of Use
Field means any field of use including, without limitation, the treatment of oncology indications.

The technology is a clinical stage novel radiopharmaceutical meant to treat different types of bone cancer and related diseases.

IPSCIO Record ID: 32574

License Grant
Licensor hereby grants to Licensee in the Field and Territory, an exclusive license under the Licensed Patents and Know-How to develop and to make, have made, use, sell, have sold and otherwise dispose of the Licensed Product.   Subject only to Licensor’s consent during the Royalty Term which shall not be unreasonably withheld or delayed having regard to the rights and obligations of Licensee under this Agreement, Licensee shall have the right to grant sublicenses of its rights granted which may, in Licensee’s discretion, convey to Sublicensees the right to grant further sublicenses.
License Property
Licensed Patents means (a) the patents and patent applications; (b) all non-provisional patent applications that claim priority to any provisional application; and (c) all divisionals, continuations, and such claims of continuations-in-part as are entitled to claim priority to the aforesaid patents and/or patent applications, and all reissues, reexaminations, extensions of, and foreign counterparts; and (d) any patents that issue with respect to the aforesaid patent applications.

Product means zoledronic acid or any combination that includes zoledronic acid. The definition includes all its various chemical forms, including derivatives acids, bases, esters, salts, isomers, enantiomers, pro-drug forms, metabolites, hydrates, solvates, polymorphs and degradants thereof in crystal, powder or other form and improvements, including new formulations and combinations.

Zoledronic acid is used to treat osteoporosis and hypercalcemia (high levels of calcium in the blood).  It can also be used to treat a cancer called multiple myeloma (tumors formed by the cells of the bone marrow) and also certain types of bone metastases (the spread of cancer to the bone).

Field of Use
Field means, and is limited to, veterinary and human therapeutic and diagnostic products and the manufacture, use and sale thereof.

IPSCIO Record ID: 330325

License Grant
Licensor granted a worldwide exclusive, sublicensable license to certain Licensor owned provisional patent applications and any patents issuing therefrom, including all continuations, continuations-in-part, divisions, extensions, substitutions, reissues, re-examinations, and any applications and all patents issuing from any applications and patents that claim domestic benefit or foreign priority to the provisional patent applications.

The Agreement also grants a contingent right to License certain other University licensed Patent Rights, to negotiate with Licensor, to obtain a nonexclusive sublicense in the field of cancer and treating cancer, including neuroinflammatory diseases occurring in any patient diagnosed with cancer.

License Property
The licensed patents relate to the use of psilocybin in cancer treatment, and any patents issuing therefrom, including all continuations, continuations-in-part, divisions, extensions, substitutions, reissues, re-examinations, and any applications and all patents issuing from any applications and patents that claim domestic benefit or foreign priority to the provisional patent applications.

Psilocybin is a naturally occurring psychedelic prodrug compound.

U.S. Provisional Patent Application No. 63/060,573, titled “Central Nervous System Delivery of Psilocybin”

U.S. Provisional Patent Application No. 63/060,569, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin”

U.S. Provisional Patent Application No. 63/060,577, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin”

U.S. Provisional Patent Application No. 63/24,827, titled “Use of Psilocybin in Cancer Treatment”

Field of Use
“Field of Use” means treatment of cancer and symptoms caused by cancer, including but not limited to pain, nausea, neuroinflammation, brain and neural dysfunction, depression, seizures, confusion, dizziness, numbness/tingling, dysfunction of the senses and all other symptoms that are caused by cancer of any type. For the sake of clarity, the Field of Use does not include any potential applications of the Licensed Products and Licensed Processes other than those used in treating cancers and the symptoms caused by the cancers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.